All In Biotech

Free tool

FAERS Monitor: Multaq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022425 or its brand name (Multaq, Dronedarone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

10,242

Serious

7,225

71% of reports

Hospitalization

3,376

Death reported

673

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • atrial fibrillation1,428
  • dyspnoea850
  • fatigue627
  • off label use571
  • diarrhoea487
  • nausea479
  • drug interaction471
  • dizziness454
  • gastrointestinal haemorrhage421
  • asthenia385
  • drug ineffective337
  • blood creatinine increased311
  • headache241
  • malaise224
  • cardiac failure223

Reports by year received

View as table
YearReports
2009200
20101,088
20111,499
2012632
2013789
2014747
2015787
2016645
2017483
2018471
2019501
2020405
2021318
2022302
2023294
2024327
2025413
2026341

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,917 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
atrial fibrillationSignal1,42830.529.140,368
gastrointestinal haemorrhageSignal42110.49.53,560
blood creatinine increasedSignal3119.88.82,452
drug interactionSignal4716.15.62,018
cardiac failureSignal2235.75.0864
dyspnoeaSignal8503.12.91,228
astheniaSignal3852.11.9226
dizziness4541.91.7187
fatigue6271.71.5168
diarrhoea4871.51.497
off label use5711.31.251
nausea4791.21.123
malaise2241.00.90
headache2410.80.714
drug ineffective3370.50.5154

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.